作者
L Zhovtis Ryerson, TC Frohman, J Foley, I Kister, B Weinstock-Guttman, C Tornatore, K Pandey, S Donnelly, S Pawate, R Bomprezzi, D Smith, C Kolb, S Qureshi, Darin Okuda, J Kalina, Z Rimler, R Green, N Monson, T Hoyt, M Bradshaw, J Fallon, E Chamot, M Bucello, S Beh, G Cutter, E Major, J Herbert, EM Frohman
发表日期
2016/8/1
期刊
Journal of Neurology, Neurosurgery & Psychiatry
卷号
87
期号
8
页码范围
885-889
出版商
BMJ Publishing Group Ltd
简介
Background
Natalizumab (NTZ), a monoclonal antibody to human α4β1/β7 integrin, is an effective therapy for multiple sclerosis (MS), albeit associated with progressive multifocal leukoencephalopathy (PML). Clinicians have been extending the dose of infusions with a hypothesis of reducing PML risk. The aim of the study is to evaluate the clinical consequences of reducing NTZ frequency of infusion up to 8 weeks 5 days.
Methods
A retrospective chart review in 9 MS centres was performed in order to identify patients treated with extended interval dosing (EID) regimens of NTZ. Patients were stratified into 3 groups based on EID NTZ treatment schedule in individual centres: early extended dosing (EED; n=249) every 4 weeks 3 days to 6 weeks 6 days; late extended dosing (LED; n=274) every 7 weeks to 8 weeks 5 days; variable extended dosing (n=382) alternating between EED and LED. These groups …
学术搜索中的文章
LZ Ryerson, TC Frohman, J Foley, I Kister… - Journal of Neurology, Neurosurgery & Psychiatry, 2016